Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis

Journal of the American Academy of Dermatology

Volumn 69, Issue 5, 2013, Pages 708-720

  Ensslin, Courtney J ^a   Rosen, Alyx C ^a   Wu, Shenhong ^b   Lacouture, Mario E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Bcr Abl; cancer; CD20; epidermal growth factor receptor; inhibitor; itch; mammalian target of rapamycin; pruritus; Raf; vascular endothelial growth factor receptor

Indexed keywords

EID: 84885623104     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.06.038     Document Type: Article

References (168)

1. S. Ricciardi, S. Tomao, and F. de Marinis Toxicity of targeted therapy in non-small-cell lung cancer management Clin Lung Cancer 10 2009 28 35
2. Y. Balagula, M.E. Lacouture, and J.A. Cotliar Dermatologic toxicities of targeted anticancer therapies J Support Oncol 8 2010 149 161
3. L.I. Wagner, S.R. Berg, M. Gandhi, F.J. Hlubocky, K. Webster, and M. Aneja The development of a functional assessment of cancer therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18) Support Care Cancer 21 2013 1033 1041
4. S.L. Boone, A. Rademaker, D. Liu, C. Pfeiffer, D.J. Mauro, and M.E. Lacouture Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results Oncology 72 2007 152 159
5. M. Gandhi, K. Oishi, B. Zubal, and M.E. Lacouture Unanticipated toxicities from anticancer therapies: survivors' perspectives Support Care Cancer 18 2010 1461 1468
6. A.C. Rosen, E.C. Case, S.W. Dusza, Y. Balagula, J. Gordon, D.P. West, and M.E. Lacouture Impact of dermatologic adverse events on quality of life in 283 cancer patients: A questionnaire study in a dermatology referral clinic Am J Clin Dermatol 14 2013 327 333
7. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
8. J. Lau, J.P. Ioannidis, and C.H. Schmid Quantitative synthesis in systematic reviews Ann Intern Med 127 1997 820 826
9. C. Renner, P.L. Zinzani, R. Gressin, D. Klingbiel, P.Y. Dietrich, and F. Hitz A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma Haematologica 97 2012 1085 1091
10. T. Doi, K. Muro, N. Boku, Y. Yamada, T. Nishina, and H. Takiuchi Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer J Clin Oncol 28 2010 1904 1910
11. R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, and S. Bracarda Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
12. J.C. Yao, C. Lombard-Bohas, E. Baudin, L.K. Kvols, P. Rougier, and P. Ruszniewski Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial J Clin Oncol 28 2010 69 76
13. P. Varadarajan, A.P. Kotsakis, D. Martin, J.S. Gutkind, M.K. Gibson, and A. Argiris Phase II trial of everolimus in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) [abstract] J Clin Oncol 30 Suppl 2012
14. A.M. Oza, L. Elit, M.S. Tsao, S. Kamel-Reid, J. Biagi, and D.M. Provencher Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical trials group J Clin Oncol 29 2011 3278 3285
15. G. Hess, R. Herbrecht, J. Romaguera, G. Verhoef, M. Crump, and C. Gisselbrecht Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma J Clin Oncol 27 2009 3822 3829
16. I. Duran, J. Kortmansky, D. Singh, H. Hirte, W. Kocha, and G. Goss A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas Br J Cancer 95 2006 1148 1154
17. M.B. Atkins, M. Hidalgo, W.M. Stadler, T.F. Logan, J.P. Dutcher, and G.R. Hudes Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 2004 909 918
18. A. Guidetti, C. Carlo-Stella, S.L. Locatelli, W. Malorni, M. Pierdominici, and C. Barbati Phase II study of sorafenib in patients with relapsed or refractory lymphoma Br J Haematol 158 2012 108 119
19. G. Grignani, E. Palmerini, P. Dileo, S.D. Asaftei, L. D'Ambrosio, and Y. Pignochino A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian sarcoma group study Ann Oncol 23 2012 508 516
20. S. Naito, T. Tsukamoto, M. Murai, K. Fukino, and H. Akaza Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma BJU Int 108 2011 1813 1819
21. G. Procopio, E. Verzoni, S. Bracarda, S. Ricci, C. Sacco, and L. Ridolfi Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial Br J Cancer 104 2011 1256 1261
22. E.T. Lam, M.D. Ringel, R.T. Kloos, T.W. Prior, M.V. Knopp, and J. Liang Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer J Clin Oncol 28 2010 2323 2330
23. M.R. Safarinejad Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a phase II study Urol Oncol 28 2010 21 27
24. G. Bianchi, S. Loibl, C. Zamagni, S. Salvagni, G. Raab, and S. Siena Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer Anticancer Drugs 20 2009 616 624
25. G.R. Blumenschein Jr., U. Gatzemeier, F. Fossella, D.J. Stewart, L. Cupit, and F. Cihon Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer J Clin Oncol 27 2009 4274 4280
26. B. Escudier, C. Szczylik, T.E. Hutson, T. Demkow, M. Staehler, and F. Rolland Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1280 1289
27. R.T. Kloos, M.D. Ringel, M.V. Knopp, N.C. Hall, M. King, and R. Stevens Phase II trial of sorafenib in metastatic thyroid cancer J Clin Oncol 27 2009 1675 1684
28. K.N. Chi, S.L. Ellard, S.J. Hotte, P. Czaykowski, M. Moore, and J.D. Ruether A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer Ann Oncol 19 2008 746 751
29. W.L. Dahut, C. Scripture, E. Posadas, L. Jain, J.L. Gulley, and P.M. Arlen A phase II clinical trial of sorafenib in androgen-independent prostate cancer Clin Cancer Res 14 2008 209 214
30. V. Gupta-Abramson, A.B. Troxel, A. Nellore, K. Puttaswamy, M. Redlinger, and K. Ransone Phase II trial of sorafenib in advanced thyroid cancer J Clin Oncol 26 2008 4714 4719
31. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
32. K.T. Flaherty, M. Redlinger, L.M. Schuchter, C.D. Lathia, B.L. Weber, and P.J. O'Dwyer Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma [abstract] J Clin Oncol 23 Suppl 2005
33. B. Escudier, T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, and M. Staehler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
34. K.C. Bible, V.J. Suman, J.R. Molina, R.C. Smallridge, W.J. Maples, and M.E. Menefee Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study Lancet Oncol 11 2010 962 972
35. F.M. Iwamoto, K.R. Lamborn, H.I. Robins, M.P. Mehta, S.M. Chang, and N.A. Butowski Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American brain tumor consortium study 06-02) Neuro Oncol 12 2010 855 861
36. B.J. Monk, L. Mas Lopez, J.J. Zarba, A. Oaknin, C. Tarpin, and W. Termrungruanglert Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer J Clin Oncol 28 2010 3562 3569
37. J.A. Sosman, K.B. Kim, L. Schuchter, R. Gonzalez, A.C. Pavlick, and J.S. Weber Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714
38. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, and J. Larkin Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
39. S.M. Goldinger, J.D. Rinderknecht, B. Belloni, N. Eggmann, and R. Dummer Cutaneous side effects (cAE) of vemurafenib (V): single-center cohort study of 28 metastatic melanoma (mM) patients (pts) [abstract] J Clin Oncol 30 Suppl 2012
40. J.A. Chan, L.S. Blaszkowsky, P.C. Enzinger, D.P. Ryan, T.A. Abrams, and A.X. Zhu A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma Ann Oncol 22 2011 1367 1373
41. E. Maubec, P. Petrow, I. Scheer-Senyarich, P. Duvillard, L. Lacroix, and J. Gelly Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin J Clin Oncol 29 2011 3419 3426
42. S.S. Ramalingam, J.W. Lee, C.P. Belani, S.C. Aisner, J. Kolesar, and C. Howe Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern cooperative oncology group phase II study (ECOG 1504) J Clin Oncol 29 2011 1709 1714
43. J.W. Neal, R.S. Heist, P. Fidias, J.S. Temel, M. Huberman, and J.P. Marcoux Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy J Thorac Oncol 5 2010 1855 1858
44. L.D. Locati, P. Bossi, F. Perrone, P. Potepan, F. Crippa, and L. Mariani Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study Oral Oncol 45 2009 574 578
45. A.X. Zhu, K. Stuart, L.S. Blaszkowsky, A. Muzikansky, D.P. Reitberg, and J.W. Clark Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma Cancer 110 2007 581 589
46. J.E. Cortes, D. Jones, S. O'Brien, E. Jabbour, F. Ravandi, and C. Koller Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia J Clin Oncol 28 2010 398 404
47. N.P. Shah, D.W. Kim, H. Kantarjian, P. Rousselot, P.E. Llacer, and A. Enrico Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib Haematologica 95 2010 232 240
48. C. Cauchi, N. Somaiah, P.F. Engstrom, S. Litwin, M. Lopez, and J. Lee Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib Cancer Chemother Pharmacol 69 2012 977 982
49. F.J. Giles, P.D. le Coutre, J. Pinilla-Ibarz, R.A. Larson, N. Gattermann, and O.G. Ottmann Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study Leukemia 27 2013 107 112
50. F.E. Nicolini, A. Turkina, Z.X. Shen, N. Gallagher, S. Jootar, and B.L. Powell Expanding nilotinib access in clinical trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase Cancer 118 2012 118 126
51. P. Reichardt, J.Y. Blay, H. Gelderblom, M. Schlemmer, G.D. Demetri, and B. Bui-Nguyen Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib Ann Oncol 23 2012 1680 1687
52. + ALL: a 36-month analysis of a phase I and II study Int J Hematol 95 2012 409 419
53. J.H. Cho, K.M. Kim, M. Kwon, J.H. Kim, and J. Lee Nilotinib in patients with metastatic melanoma harboring KIT gene aberration Invest New Drugs 30 2012 2008 2014
54. F.J. Giles, E. Abruzzese, G. Rosti, D.W. Kim, R. Bhatia, and A. Bosly Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy Leukemia 24 2010 1299 1301
55. G. Saglio, D.W. Kim, S. Issaragrisil, P. le Coutre, G. Etienne, and C. Lobo Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 2010 2251 2259
56. +) chronic myeloid leukemia Blood 114 2009 4933 4938
57. P. le Coutre, O.G. Ottmann, F. Giles, D.W. Kim, J. Cortes, and N. Gattermann Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia Blood 111 2008 1834 1839
58. M. Schlemmer, S. Bauer, R. Schutte, J.T. Hartmann, C. Bokemeyer, and C. Hosius Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial Eur J Med Res 16 2011 206 212
59. D. Kerob, R. Porcher, O. Verola, S. Dalle, E. Maubec, and F. Aubin Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients Clin Cancer Res 16 2010 3288 3295
60. A.Y. Lin, G.A. Fisher, S. So, C. Tang, and L. Levitt Phase II study of imatinib in unresectable hepatocellular carcinoma Am J Clin Oncol 31 2008 84 88
61. T. Nishida, K. Shirao, A. Sawaki, M. Koseki, T. Okamura, and A. Ohtsu Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202) Int J Clin Oncol 13 2008 244 251
62. G.K. Bajaj, Z. Zhang, E. Garrett-Mayer, R. Drew, V. Sinibaldi, and R. Pili Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy Urology 69 2007 526 531
63. P.Y. Wen, W.K. Yung, K.R. Lamborn, P.L. Dahia, Y. Wang, and B. Peng Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American brain tumor consortium study 99-08 Clin Cancer Res 12 2006 4899 4907
64. G. Hess, D. Bunjes, W. Siegert, R. Schwerdtfeger, G. Ledderose, and B. Wassmann Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study J Clin Oncol 23 2005 7583 7593
65. K. Rao, S. Goodin, M.J. Levitt, N. Dave, W.J. Shih, and Y. Lin A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer Prostate 62 2005 115 122
66. J. Verweij, P.G. Casali, J. Zalcberg, A. LeCesne, P. Reichardt, and J.Y. Blay Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomized trial Lancet 364 2004 1127 1134
67. S.G. O'Brien, F. Guilhot, R.A. Larson, I. Gathmann, M. Baccarani, and F. Cervantes Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004
68. H. Kantarjian, C. Sawyers, A. Hochhaus, F. Guilhot, C. Schiffer, and C. Gambacorti-Passerini Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 2002 645 652
69. M. Talpaz, R.T. Silver, B.J. Druker, J.M. Goldman, C. Gambacorti-Passerini, and F. Guilhot Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood 99 2002 1928 1937
70. B. Kang, J. Lee, M. Ryu, S. Im, S. Park, and W. Kang A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors [abstract] J Clin Oncol 27 Suppl 2009
71. C.M. Lewis, B.S. Glisson, L. Feng, F. Wan, X. Tang, and Wistuba II A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck Clin Cancer Res 18 2012 1435 1446
72. S.J. Park, H.T. Kim, D.H. Lee, K.P. Kim, S.W. Kim, and C. Suh Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation Lung Cancer 77 2012 556 560
73. L. Zhang, S. Ma, X. Song, B. Han, Y. Cheng, and C. Huang Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicenter, double-blind randomized phase 3 trial Lancet Oncol 13 2012 466 475
74. K. Asami, T. Koizumi, K. Hirai, S. Ameshima, A. Tsukadaira, and N. Morozumi Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano lung cancer research group study Clin Lung Cancer 12 2011 387 392
75. X. Chen, W. Li, X. Hu, Y. Geng, R. Wang, and Y. Yin Effect of gefitinib challenge to initial treatment with non-small cell lung cancer Biomed Pharmacother 65 2011 542 546
76. D.W. Kim, S.H. Lee, J.S. Lee, M.A. Lee, J.H. Kang, and S.Y. Kim A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations Lung Cancer 71 2011 65 69
77. D.H. Lee, K. Park, J.H. Kim, J.S. Lee, S.W. Shin, and J.H. Kang Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy Clin Cancer Res 16 2010 1307 1314
78. M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi, and H. Isobe Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
79. G. Goss, D. Ferry, R. Wierzbicki, S.A. Laurie, J. Thompson, and B. Biesma Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status J Clin Oncol 27 2009 2253 2260
80. H. Lara-Guerra, T.K. Waddell, M.A. Salvarrey, A.M. Joshua, C.T. Chung, and N. Paul Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer J Clin Oncol 27 2009 6229 6236
81. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, and N. Saijo Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
82. R. Maruyama, Y. Nishiwaki, T. Tamura, N. Yamamoto, M. Tsuboi, and K. Nakagawa Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer J Clin Oncol 26 2008 4244 4252
83. N. Sunaga, Y. Tomizawa, N. Yanagitani, H. Iijima, K. Kaira, and K. Shimizu Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy Lung Cancer 56 2007 383 389
84. H. Asahina, K. Yamazaki, I. Kinoshita, N. Sukoh, M. Harada, and H. Yokouchi A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations Br J Cancer 95 2006 998 1004
85. T. Cufer, E. Vrdoljak, R. Gaafar, I. Erensoy, and K. Pemberton Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (Iressa) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer Anticancer Drugs 17 2006 401 409
86. J.M. Xu, Y. Han, Y.M. Li, C.H. Zhao, Y. Wang, and A. Paradiso Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer BMC Cancer 6 2006 288
87. D.H. Lee, J.Y. Han, H.G. Lee, J.J. Lee, E.K. Lee, and H.Y. Kim Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers Clin Cancer Res 11 2005 3032 3037
88. A. Polychronis, H.D. Sinnett, D. Hadjiminas, H. Singhal, J.L. Mansi, and D. Shivapatham Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with estrogen-receptor positive and epidermal-growth- factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomized trial Lancet Oncol 6 2005 383 391
89. M.L. Rothenberg, B. LaFleur, D.E. Levy, M.K. Washington, S.L. Morgan-Meadows, and R.K. Ramanathan Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma J Clin Oncol 23 2005 9265 9274
90. N. Thatcher, A. Chang, P. Parikh, J. Rodrigues Pereira, T. Ciuleanu, and J. von Pawel Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicenter study (Iressa survival evaluation in lung cancer) Lancet 366 2005 1527 1537
91. M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, and J.Y. Douillard Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected] J Clin Oncol 21 2003 2237 2246
92. C. Defferrari, M. Loprevite, A. Brianti, G. Catania, F. Grossi, and P. Pronzato Difference between skin toxicities in erlotinib (E) and gefitinib (G) in the treatment of advanced non-small cell lung cancer (NSCLC) [abstract] J Clin Oncol 25 Suppl 2007
93. F.J. Giles, W.T. Bellamy, Z. Estrov, S.M. O'Brien, S. Verstovsek, and F. Ravandi The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) Leuk Res 30 2006 801 811
94. K. Tobinai, T. Igarashi, K. Itoh, M. Kurosawa, H. Nagai, and A. Hiraoka Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study Cancer Sci 102 2011 1698 1705
95. M.A. Gertz, M. Rue, E. Blood, L.S. Kaminer, D.H. Vesole, and P.R. Greipp Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern cooperative oncology group study (E3A98) Leuk Lymphoma 45 2004 2047 2055
96. K. Tobinai, T. Igarashi, K. Itoh, Y. Kobayashi, M. Taniwaki, and M. Ogura Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma Ann Oncol 15 2004 821 830
97. + Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin lymphoma study group Blood 101 2003 420 424
98. T. Igarashi, Y. Kobayashi, M. Ogura, T. Kinoshita, T. Ohtsu, and Y. Sasaki Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study Ann Oncol 13 2002 928 943
99. T.A. Davis, A.J. Grillo-Lopez, C.A. White, P. McLaughlin, M.S. Czuczman, and B.K. Link Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment J Clin Oncol 18 2000 3135 3143
100. J.M. Foran, R.K. Gupta, D. Cunningham, R.A. Popescu, A.H. Goldstone, and J.W. Sweetenham A UK multicenter phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response Br J Haematol 109 2000 81 88
101. L.D. Piro, C.A. White, A.J. Grillo-Lopez, N. Janakiraman, A. Saven, and T.M. Beck Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma Ann Oncol 10 1999 655 661
102. B. Coiffier, C. Haioun, N. Ketterer, A. Engert, H. Tilly, and D. Ma Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study Blood 92 1998 1927 1932
103. H. Cortes-Funes, J. de la Serna, E. Flores, G. Perez Manga, A. Lopez, and C. Palacios Rituximab in monotherapy in patients with relapsed follicular or low grade B-cell non-Hodgkin's lymphoma: results after a six month follow-up cut-off Proc Am Soc Clin Oncol 19 2000
104. E.M. Hersh, S.J. O'Day, J. Powderly, K.D. Khan, A.C. Pavlick, and L.D. Cranmer A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma Invest New Drugs 29 2011 489 498
105. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
106. J.D. Wolchok, B. Neyns, G. Linette, S. Negrier, J. Lutzky, and L. Thomas Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomized, double-blind, multicenter, phase 2, dose-ranging study Lancet Oncol 11 2010 155 164
107. E. Simeone, G. Gentilcore, A. Romano, A. Daponte, C. Caraco, and A.M. Grimaldi Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival J Clin Oncol 30 2012
108. M.S. Kaminski, J.A. Radford, S.A. Gregory, J.P. Leonard, S.J. Knox, and S. Kroll Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab J Clin Oncol 23 2005 7985 7993
109. M.S. Kaminski, A.D. Zelenetz, O.W. Press, M. Saleh, J. Leonard, and L. Fehrenbacher Pivotal study of iodine I 131 tositumomab for chemotherapy- refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas J Clin Oncol 19 2001 3918 3928
110. J.M. Vose, R.L. Wahl, M. Saleh, A.Z. Rohatiner, S.J. Knox, and J.A. Radford Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas J Clin Oncol 18 2000 1316 1323
111. T. Ciuleanu, L. Stelmakh, S. Cicenas, S. Miliauskas, A.C. Grigorescu, and C. Hillenbach Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomized multicenter, open-label, phase 3 study Lancet Oncol 13 2012 300 308
112. B. Coudert, T. Ciuleanu, K. Park, Y.L. Wu, G. Giaccone, and W. Brugger Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy Ann Oncol 23 2012 388 394
113. D.R. Choi, D.H. Lee, C.M. Choi, S.W. Kim, C. Suh, and J.S. Lee Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study Anticancer Res 31 2011 3457 3462
114. D.H. Lee, S.W. Kim, C. Suh, Y.H. Han, and J.S. Lee Phase II study of erlotinib for chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets Cancer Chemother Pharmacol 67 2011 35 39
115. R.B. Natale, S. Thongprasert, F.A. Greco, M. Thomas, C.M. Tsai, and P. Sunpaweravong Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer J Clin Oncol 29 2011 1059 1066
116. L.V. Sequist, J. von Pawel, E.G. Garmey, W.L. Akerley, W. Brugger, and D. Ferrari Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer J Clin Oncol 29 2011 3307 3315
117. F. Cappuzzo, T. Ciuleanu, L. Stelmakh, S. Cicenas, A. Szczesna, and E. Juhasz Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicenter, randomized, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
118. T. Takahashi, N. Yamamoto, T. Nukiwa, K. Mori, M. Tsuboi, and T. Horai Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer Anticancer Res 30 2010 557 563
119. M.N. Dickler, M.A. Cobleigh, K.D. Miller, P.M. Klein, and E.P. Winer Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer Breast Cancer Res Treat 115 2009 115 121
120. K. Kubota, Y. Nishiwaki, T. Tamura, K. Nakagawa, K. Matsui, and K. Watanabe Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study J Thorac Oncol 3 2008 1439 1445
121. A.M. Oza, E.A. Eisenhauer, L. Elit, J.C. Cutz, A. Sakurada, and M.S. Tsao Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148 J Clin Oncol 26 2008 4319 4325
122. L.L. Garland, C. Rankin, D.R. Gandara, S.E. Rivkin, K.M. Scott, and R.B. Nagle Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest oncology group study J Clin Oncol 25 2007 2406 2413
123. M.B. Thomas, R. Chadha, K. Glover, X. Wang, J. Morris, and T. Brown Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma Cancer 110 2007 1059 1067
124. T. Dragovich, S. McCoy, C.M. Fenoglio-Preiser, J. Wang, J.K. Benedetti, and A.F. Baker Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127 J Clin Oncol 24 2006 4922 4927
125. A.N. Gordon, N. Finkler, R.P. Edwards, A.A. Garcia, M. Crozier, and D.H. Irwin Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study Int J Gynecol Cancer 15 2005 785 792
126. P.A. Philip, M.R. Mahoney, C. Allmer, J. Thomas, H.C. Pitot, and G. Kim Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer J Clin Oncol 23 2005 6657 6663
127. R. Perez-Soler Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer Clin Lung Cancer 6 Suppl 2004 S20 S23
128. D. Soulieres, N.N. Senzer, E.E. Vokes, M. Hidalgo, S.S. Agarwala, and L.L. Siu Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck J Clin Oncol 22 2004 77 85
129. J.W. Neal, N.A. Pennell, B.W. Goodgame, M. Lanuti, R.S. Heist, and A.T. Shaw A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): toxicity evaluation [abstract] J Clin Oncol 28 Suppl 2010
130. K.V. Jasas, A. Fyles, L. Elit, P.J. Hoskins, J. Biagi, and J. Dubuc-Lissoir Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND-148 [abstract] J Clin Oncol 22 Suppl 2004
131. N.S. Horowitz, A.B. Olawaiye, D.R. Borger, W.B. Growdon, C.N. Krasner, and U.A. Matulonis Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva Gynecol Oncol 127 2012 141 146
132. S.S. Ramalingam, F. Blackhall, M. Krzakowski, C.H. Barrios, K. Park, and I. Bover Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer J Clin Oncol 30 2012 3337 3344
133. E.E. Schaake, I. Kappers, H.E. Codrington, R.A. Valdes Olmos, H.J. Teertstra, and R. van Pel Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer J Clin Oncol 30 2012 2731 2738
134. J.R. Hecht, E. Mitchell, M.A. Neubauer, H.A. Burris III, P. Swanson, and T. Lopez Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer Clin Cancer Res 16 2010 2205 2213
135. K. Muro, T. Yoshino, T. Doi, K. Shirao, H. Takiuchi, and Y. Hamamoto A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer Jpn J Clin Oncol 39 2009 321 326
136. E. Van Cutsem, M. Peeters, S. Siena, Y. Humblet, A. Hendlisz, and B. Neyns Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer J Clin Oncol 25 2007 1658 1664
137. E. Van Cutsem, S. Siena, Y. Humblet, J.L. Canon, J. Maurel, and E. Bajetta An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy Ann Oncol 19 2008 92 98
138. Y. Yamada, T. Tamura, K. Shirao, T. Doi, M. Tahara, and K. Minashi Safety and pharmacokinetics (PK) of panitumumab in Japanese patients (pts) with advanced solid malignancies [abstract] J Clin Oncol Suppl 2007
139. Y.E. Whang, A.J. Armstrong, W.K. Rathmell, P.A. Godley, W.Y. Kim, and R.S. Pruthi A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer Urol Oncol 31 2013 82 86
140. B. Thiessen, C. Stewart, M. Tsao, S. Kamel-Reid, P. Schaiquevich, and W. Mason A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation Cancer Chemother Pharmacol 65 2010 353 361
141. T. Bekaii-Saab, J. Markowitz, N. Prescott, W. Sadee, N. Heerema, and L. Wei A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas Clin Cancer Res 15 2009 5895 5901
142. K.L. Blackwell, M.D. Pegram, E. Tan-Chiu, L.S. Schwartzberg, M.C. Arbushites, and J.D. Maltzman Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens Ann Oncol 20 2009 1026 1031
143. M. Toi, H. Iwata, Y. Fujiwara, Y. Ito, S. Nakamura, and Y. Tokuda Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies Br J Cancer 101 2009 1676 1682
144. H.L. Gomez, D.C. Doval, M.A. Chavez, P.C. Ang, Z. Aziz, and S. Nag Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer J Clin Oncol 26 2008 2999 3005
145. S. Johnston, M. Trudeau, B. Kaufman, H. Boussen, K. Blackwell, and P. LoRusso Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy J Clin Oncol 26 2008 1066 1072
146. M. Agulnik, E.W. Cohen, R.B. Cohen, E.X. Chen, E.E. Vokes, and S.J. Hotte Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands J Clin Oncol 25 2007 3978 3984
147. C. Hsu, T.S. Yang, T.I. Huo, R.K. Hsieh, C.W. Yu, and W.S. Hwang Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study J Hepatol 56 2012 1097 1103
148. J.S. Lee, V. Hirsh, K. Park, S. Qin, C.R. Blajman, and R.P. Perng Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR) J Clin Oncol 30 2012 1114 1121
149. L. Peuvrel, C. Bachmeyer, Z. Reguiai, J.B. Bachet, T. Andre, and R.J. Bensadoun Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors Support Care Cancer 20 2012 909 921
150. D. Santini, B. Vincenzi, F.M. Guida, M. Imperatori, G. Schiavon, and O. Venditti Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study Lancet Oncol 13 2012 1020 1024
151. S. Segaert, and E. Van Cutsem Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors Ann Oncol 16 2005 1425 1433
152. A.F. Galimont-Collen, L.E. Vos, A.P. Lavrijsen, J. Ouwerkerk, and H. Gelderblom Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors Eur J Cancer 43 2007 845 851
153. E. Roe, M.P. Garcia Muret, E. Marcuello, J. Capdevila, C. Pallares, and A. Alomar Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients J Am Acad Dermatol 55 2006 429 437
154. M. Karthaus, R. Hofheinz, L. Mineur, H. Letocha, R. Greil, and J. Thaler Epidermal growth factor receptor (EGFR) inhibitor-related skin toxicity: review of interim data from a phase II study (2260314) of panitumumab with FOLFIRI in the first-line treat- ment of metastatic colorectal cancer J Clin Oncol 27 2009 e20364
155. B. Ledezma Ipilimumab for advanced melanoma: a nursing perspective Oncol Nurs Forum 36 2009 97 104
156. R.S. Fallen, C.R. Terpstra, and H.C. Lima Immunotherapies in dermatologic disorders Med Clin North Am 96 2012 565 582 x-xi
157. Y. Balagula, S. Wu, X. Su, and M.E. Lacouture The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis Ann Oncol 22 2011 2366 2374
158. G. Yosipovitch, and J.D. Bernhard Clinical practice: chronic pruritus N Engl J Med 368 2013 1625 1634
159. X. Su, M.E. Lacouture, Y. Jia, and S. Wu Risk of high-grade skin rash in cancer patients treated with cetuximab-an antibody against epidermal growth factor receptor: systemic review and meta-analysis Oncology 77 2009 124 133
160. Y. Inami, T. Andoh, A. Sasaki, and Y. Kuraishi Topical surfactant-induced pruritus: involvement of histamine released from epidermal keratinocytes J Pharmacol Exp Ther 344 2013 459 466
161. P.A. Gerber, B.A. Buhren, F. Cevikbas, E. Bolke, M. Steinhoff, and B. Homey Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus J Am Acad Dermatol 63 2010 163 165
162. A. Ikoma, M. Steinhoff, S. Stander, G. Yosipovitch, and M. Schmelz The neurobiology of itch Nat Rev Neurosci 7 2006 535 547
163. P.A. Yosipovitch Pruritus M.E. Lacouture, Dermatologic principles and practice in oncology 2014 John Wiley & Sons, Inc Hoboken, NJ
164. S.C. Chen Pruritus Dermatol Clin 30 2012 309 321 ix
165. N. Penel, A. Le Cesne, B.N. Bui, D. Perol, E.G. Brain, and I. Ray-Coquard Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French sarcoma group phase II trial with a long-term follow-up Ann Oncol 22 2011 452 457
166. I.W. Graziadei, A. Finkenstedt, R. Stauber, M. Trauner, C. Mueller, and W. Vogel Imatinib treatment for patients with advanced stage hepatocellular carcinoma: a multicenter phase II trial [abstract] J Clin Oncol 28 Suppl 2010
167. A.M. Lin, B.I. Rini, V. Weinberg, K. Fong, C.J. Ryan, and J.E. Rosenberg A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy BJU Int 98 2006 763 769
168. S. Gellrich, J.M. Muche, A. Wilks, K.C. Jasch, C. Voit, and T. Fischer Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas-an applicational observation Br J Dermatol 153 2005 167 173